Centre Jean Perrin

Centre Jean Perrin is the Centre de Lutte Contre le Cancer for Clermont-Ferrand and the Auvergne, one of the 18 Unicancer centres in France. It provides surgical oncology, medical oncology, radiotherapy, nuclear medicine and supportive care, and hosts an Inserm research unit (Imagerie Moléculaire et Stratégies Théranostiques) focused on molecular imaging and radiopharmaceuticals, including melanoma-targeting tracers. The centre is accredited by the Organisation of European Cancer Institutes as a Comprehensive Cancer Centre and works closely with the CHU de Clermont-Ferrand and the Université Clermont Auvergne.

Location

Clermont-Ferrand, FR

Type

cancer center

Website

www.cjp.fr

Newsweek 2026 oncology rank

Not in top 300 listing used

OnCo score

#498 · 6 points (0 Newsweek + 0 NCI + 6 from 3 linked objects) · ranking

Research output

From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.

Matched to Centre Jean Perrin, including child institutions. 107 works · 1,229 citations · 75% open access · 14% clinical trials · 2% reviews.

Oncology works per year

192022

282023

302024

192025

112026

Most works

Most cited

Work	Journal	Year	Citations
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer 10.1016/j.annonc.2023.05.008 · open access	Annals of Oncology	2023	311
Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY) conference abstract · 10.1158/1538-7445.sabcs21-pd8-02	Cancer Research	2022	108
Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer 10.1016/j.esmoop.2023.101615 · open access	ESMO Open	2023	81
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial 10.1136/ijgc-2023-004995 · open access	International Journal of Gynecological Cancer	2023	65
Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer 10.1002/path.6165 · open access	The Journal of Pathology	2023	54
LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study conference abstract · 10.1016/j.annonc.2023.10.008 · open access	Annals of Oncology	2023	46
Selecting patients with HER2-low breast cancer: Getting out of the tangle 10.1016/j.ejca.2022.08.022 · open access	European Journal of Cancer	2022	44
Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes 10.1016/j.esmoop.2024.102236 · open access	ESMO Open	2024	43
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial 10.1016/j.annonc.2024.10.828 · open access	Annals of Oncology	2024	40
Global Study on the Accuracy of Human Epidermal Growth Factor Receptor 2-Low Diagnosis in Breast Cancer 10.5858/arpa.2024-0052-oa · open access	Archives of Pathology & Laboratory Medicine	2024	30
Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance. conference abstract · 10.1200/jco.2023.41.16_suppl.5550 · open access	Journal of Clinical Oncology	2023	30
260P Antitumor activity of trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (mBC) and brain metastases (BMs) from DAISY trial 10.1016/j.annonc.2022.07.299 · open access	Annals of Oncology	2022	26
Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years 10.1016/j.ejca.2023.113262 · open access	European Journal of Cancer	2023	23
Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics 10.1016/j.ejca.2024.115169 · open access	European Journal of Cancer	2024	22
Chemotherapy‑induced peripheral neuropathy in patients with breast cancer treated with taxanes (Review) 10.3892/ol.2025.15254 · open access	Oncology Letters	2025	20

Programmes

3top

Molecular imaging and theranostics
Radiotherapy
Breast cancer

People

1top

Frédérique Penault-Llorca

Directrice Générale (Director General), Centre Jean Perrin

PathologyBreast cancer biomarkersCancer centre management

Professor who directs Centre Jean Perrin, the comprehensive cancer centre for the Auvergne region in Clermont-Ferrand, now in her second five-year term.

Connected

4top

Institution
Institut du Cancer de Montpellier (ICM)
Shares UNICANCER, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre, unicancer.
Institution
Centre François Baclesse
Shares UNICANCER, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre, unicancer.
Institution
Centre Henri Becquerel
Shares UNICANCER, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre, unicancer.
Institution
Centre Eugène Marquis
Shares UNICANCER, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre, unicancer.
Institution
Institut de Cancérologie de l'Ouest (ICO)
Shares UNICANCER, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre, unicancer.
Institution
Hospital Universitario Fundación Jiménez Díaz
Shares Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre.
Institution
University Medical Center Groningen Comprehensive Cancer Center
Shares Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre.
Institution
ASST Spedali Civili di Brescia
Shares Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre.

Research output

Programmes

People

Connected

Similar pages

technologies

companies

institutions

people

Centre Jean Perrin

Research output

Programmes

People

Connected

Similar pages

technologies

companies

institutions

people

Centre Jean Perrin

Overview

Research output

Programmes

People

Connected

Similar pages

technologies

companies

institutions

people

Centre Jean Perrin

Overview

Research output

Programmes

People

Connected

Similar pages

technologies

companies

institutions

people